VentriJect Secures $1.7M to Launch Seismofit – Revolutionizing VO2max Testing in Just 3 Minutes!

VentriJect is excited to announce that the company has successfully raised 1,700,000 in funding—a critical milestone that will help revolutionize how we work with cardiorespiratory fitness. With cardiorespiratory fitness, measured as VO2max, being one of the strongest indicators of overall health, even the smallest improvement can lead to significant health benefits. Unfortunately, traditional evaluation methods are often cumbersome, time-consuming, expensive, and require highly trained staff. VentriJect’s breakthrough technology, Seismofit, promises to change that narrative. This innovative device reliably estimates VO2max in less than three minutes, offering a clinical-validated, patented, and user-friendly solution that makes testing more accessible to both patients and healthcare professionals. Established as a spin-out from a leading research center in cardiology at Aalborg University in 2018, VentriJect is situated in Hellerup near Copenhagen, Denmark, and has already begun to disrupt the landscape of cardiopulmonary diagnostics. The recent funding injection will be dedicated to further refining the Seismofit technology, scaling up production, and expanding market penetration globally. These resources will also support additional research and development to enhance the accuracy and usability of the device, ensuring that it remains at the forefront of medical innovation. By breaking down barriers to efficient cardiovascular assessment, VentriJect is set not only to improve clinical workflows but also to empower patients to take charge of their own heart health. This funding marks an exciting step forward in the company’s mission to make cardiorespiratory fitness testing accessible, efficient, and affordable for everyone.